Filter By Industry
Filter By Tag

Newsroom

TGV Press releases

1 - 3 of 3 Press Releases

NY Scientists First to Link Neurodegenerative Diseases and Bacterial Viruses
Oct 13, 2017
Human Microbiology Institute presents breakthrough data that may change conventional understanding of causes for many diseases NEW YORK (October 13, 2017) – Alzheimer's and many other neurodegenerative diseases can be caused by bacteriophages –...

TGV-inhalonix's Drug Candidate Shows Promise to Fight Deadly CF Lung Infections
Jun 08, 2017
The New York-based company reports its success at the 40th European Cystic Fibrosis Conference

TGV-inhalonix's New Drug to Help Save Cystic Fibrosis Patients w/ Resistant Fungal Lung Infections
May 11, 2017
TGV-inhalonix, a New York drug development company behind  ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has.


TGV RSS Feed